Cartesian Therapeutics (RNAC) Other Non Operating Income (2016 - 2025)
Historic Other Non Operating Income for Cartesian Therapeutics (RNAC) over the last 11 years, with Q2 2025 value amounting to -$5000.0.
- Cartesian Therapeutics' Other Non Operating Income fell 10171.23% to -$5000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was -$449000.0, marking a year-over-year decrease of 14544.53%. This contributed to the annual value of $606000.0 for FY2024, which is 1230.1% down from last year.
- Latest data reveals that Cartesian Therapeutics reported Other Non Operating Income of -$5000.0 as of Q2 2025, which was down 10171.23% from -$444000.0 recorded in Q4 2024.
- In the past 5 years, Cartesian Therapeutics' Other Non Operating Income registered a high of $508000.0 during Q1 2024, and its lowest value of -$444000.0 during Q4 2024.
- In the last 5 years, Cartesian Therapeutics' Other Non Operating Income had a median value of $84500.0 in 2022 and averaged $95875.0.
- Examining YoY changes over the last 5 years, Cartesian Therapeutics' Other Non Operating Income showed a top increase of 210000.0% in 2022 and a maximum decrease of 64285.71% in 2022.
- Over the past 5 years, Cartesian Therapeutics' Other Non Operating Income (Quarter) stood at $9000.0 in 2021, then surged by 1844.44% to $175000.0 in 2022, then tumbled by 135.43% to -$62000.0 in 2023, then tumbled by 616.13% to -$444000.0 in 2024, then surged by 98.87% to -$5000.0 in 2025.
- Its last three reported values are -$5000.0 in Q2 2025, -$444000.0 for Q4 2024, and $250000.0 during Q3 2024.